|
Re: Clovis' Rubracra
|
6
|
Zenith Epigenetics
|
Oct 05, 2018 11:45AM
|
|
Re: Clovis' Rubracra
|
7
|
Zenith Epigenetics
|
Oct 05, 2018 12:12PM
|
|
Re: Colchicine article from medscape
|
1
|
Resverlogix Corp.
|
Feb 10, 2021 09:29AM
|
|
Re: Collaborating with the Supreme Council of the Arab-African Economy
|
10
|
Resverlogix Corp.
|
Nov 03, 2021 07:53PM
|
|
Re: Comments on the AGM
|
8
|
Resverlogix Corp.
|
Nov 09, 2019 09:31AM
|
|
Re: Comments on today's annual update
|
8
|
Resverlogix Corp.
|
Jun 23, 2021 09:00AM
|
|
Re: Comments on today's annual update
|
9
|
Resverlogix Corp.
|
Jun 23, 2021 08:08AM
|
|
Re: Contest Tally
|
2
|
Resverlogix Corp.
|
Feb 13, 2019 10:31AM
|
|
Re: Context on Sales Potential for an oral anti-viral & anti-inflammation combo
|
5
|
Resverlogix Corp.
|
Apr 14, 2021 06:44PM
|
|
Re: Context on Sales Potential for an oral anti-viral & anti-inflammation combo
|
9
|
Resverlogix Corp.
|
Apr 15, 2021 11:58AM
|
|
Re: Corporate Update Webcast and Conference Call December 16, 2021 @ 2 PM MST
|
9
|
Resverlogix Corp.
|
Dec 15, 2021 02:05PM
|
|
Re: Corporate Update Webcast and Conference Call December 16, 2021 @ 2 PM MST
|
7
|
Resverlogix Corp.
|
Dec 15, 2021 05:25PM
|
|
Re: Could it be
|
5
|
Zenith Epigenetics
|
Oct 27, 2023 02:59PM
|
|
Re: Covid 19 trial
|
7
|
Resverlogix Corp.
|
Jun 03, 2021 01:43PM
|
|
Re: Covid China
|
11
|
Resverlogix Corp.
|
Mar 30, 2022 01:46PM
|
|
Re: Covid link to diabetes
|
5
|
Resverlogix Corp.
|
May 05, 2021 06:48PM
|
|
Re: Covid PIII Questions and Thoughts
|
7
|
Resverlogix Corp.
|
May 27, 2022 11:49AM
|
|
Re: Crazy Question
|
7
|
Resverlogix Corp.
|
Jan 06, 2024 10:12AM
|
|
Re: CRISPR vs. BET inhibitors
|
3
|
Resverlogix Corp.
|
Jan 10, 2016 06:16PM
|
|
Re: CRISPR vs. BET inhibitors
|
2
|
Resverlogix Corp.
|
Jan 10, 2016 11:10PM
|
